Mabtas (Rituximab) is manufactured by Intas Biopharmaceuticals Ltd
Mabtas (Rituximab) is available in two strengths - 100mg/10ml & 500mg/50ml
Rituximab (generic Mabthera) is a monoclonal antibody, which is a type of biological therapy. Intas Biopharmaceuticals Ltd manufactures Rituximab by brand name, Mabtas.
Rituximab (generic Mabthera) is a treatment for chronic lymphocytic leukemia and some types of non Hodgkin lymphoma. Rituximab (generic Mabthera) is also used for some non cancer related illnesses.
Rituximab (generic Mabthera) targets a protein called CD20 on the surface of the leukemia and lymphoma cells. The antibody sticks to all the CD20 proteins it finds. Then the cells of the immune system pick out the marked cells and kill them.